Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing ...
The RSV shot — the first ever drug using mRNA technology approved for a disease other than COVID — gives it another ...
The panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at ...
The jury found that AstraZeneca's Tagrisso violated Pfizer's Wyeth unit's patent rights under US patents 10,603,314 and ...
Manufacturing is underway and doses of Moderna’s Spikevax 2024-2025 formula will be ready to ship as early as August, pending ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Synthesia's new technology is impressive but raises big questions about a world where we increasingly can’t tell what’s real. The FDA is poised to approve the notorious party drug as a therapy. Here’s ...
Drug manufactures Moderna, Pfizer and Novavax said they expect the new vaccines will be available this fall in time for flu ...
Moderna (MRNA) stock gains as the U.S. is close to fund a late-stage trial for the company's messenger-RNA-based ...
Covid-19 sub-variants, nicknamed "FLiRT", have been the dominant forms of the virus circulating this year globally, according ...
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots ...